In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MSD

Latest From MSD

Taisho Makes Japan Vornorexant Filing, Hopes To Dent Insomnia Market

Taisho’s in-house insomnia therapeutic candidate vornorexant offers a potential advantage of a shorter half-life compared to its competitors, which can contribute to patients’ QOL.

Japan Drug Review

Former Hilleman CEO On Microbiome Project, Cholera, Halal Vaccine

Human milk could have a role in preventing Alzheimer’s disease and other ailments linked to the gut microbiome, says former Pfizer VP and Hilleman CEO Davinder Gill. He also talks about a halal meningitis vaccine, and tailwinds for an oral cholera vaccine now launched by Bharat Biotech in this fascinating interview

Research & Development Vaccines

India Inc Calls For Regulatory Easing; Looks To Biosimilar Launches Including Keytruda

Speaking of an impending launch of new biosimilars, including pembrolizumab, panelists at a recent event in India asked for regulatory easing from a waiver of Phase III trials for biosimilars to a single body for pre-clinical and trial approvals. The chicken and egg question of VC funding also came up.

Commercial Business Strategies

New Zealand Gets Cracking On NZD$604m Drug Funding Boost; Starts Repealing Landmark Law

Two targeted treatments for six different types of cancer and two antifungal drugs are the first products that Pharmac has proposed should be funded after it received a boost to its budget in June. Separately, the government is seeking feedback on a bill to repeal the sweeping new therapeutic products law that was passed by its predecessor.

New Zealand Market Access
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Merck Sharpe & Dome
UsernamePublicRestriction

Register